Blinatumomab: A First-in-Class Bispecific T-Cell Engager for Precursor B-Cell Acute Lymphoblastic Leukemia (Q38515225)

3 September 2017

1 reference

title

Blinatumomab: A First-in-Class Bispecific T-Cell Engager for Precursor B-Cell Acute Lymphoblastic Leukemia (English)

1 reference

3 September 2017

1 reference

3

1 reference

3 September 2017

Larry W Buie

1

1 reference

3 September 2017

Joshua J Pecoraro

series ordinal

2

1 reference

3 September 2017

Ryan J Daley

series ordinal

4

1 reference

3 September 2017

language of work or name

English

0 references

publication date

3 June 2015

1 reference

Annals of Pharmacotherapy

3 September 2017

published in

1 reference

3 September 2017

volume

49

1 reference

3 September 2017

issue

9

1 reference

3 September 2017

page(s)

1057-1067

1 reference

Survival of adults with acute lymphoblastic leukemia in Germany and the United States

3 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1060028015588555

Advances in the molecular pathobiology of B-lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015588555

Treatment of adult acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015588555

Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015588555

Intensified and shortened cyclical chemotherapy for adult acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015588555

How I treat acute lymphocytic leukemia in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015588555

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015588555

In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolid

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015588555

The myth of the second remission of acute leukemia in the adult

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015588555

Acute lymphoblastic leukemia: monitoring minimal residual disease as a therapeutic principle

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015588555

Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015588555

Has MRD monitoring superseded other prognostic factors in adult ALL?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015588555

Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015588555

Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: data from the GMALL 06/99 and 07/03 trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015588555

Prognostic significance and treatment implications of minimal residual disease studies in Philadelphia-negative adult acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015588555

Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015588555

Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015588555

Minimal residual disease analysis for the prediction of relapse in children with standard-risk acute lymphoblastic leukaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015588555

Minimal residual disease is a significant predictor of treatment failure in non T-lineage adult acute lymphoblastic leukaemia: final results of the international trial UKALL XII/ECOG2993.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015588555

Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015588555

Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015588555

Tumor regression in cancer patients by very low doses of a T cell-engaging antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015588555

Tumor immunosurveillance in human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015588555

Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015588555

A high number of CD8+ T cells infiltrated in NSCLC tissues is associated with a favorable prognosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015588555

Type, density, and location of immune cells within human colorectal tumors predict clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015588555

CD8+ T-cell content in diagnostic lymph nodes measured by flow cytometry is a predictor of survival in follicular lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015588555

Tumor microenvironment and immune escape

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015588555

Targeting T cells to tumor cells using bispecific antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015588555

Blinatumomab: a historical perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015588555

Immunotherapy of lymphoma and leukemia with T-cell engaging BiTE antibody blinatumomab

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015588555

T-cell activation and B-cell depletion in chimpanzees treated with a bispecific anti-CD19/anti-CD3 single-chain antibody construct

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015588555

Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015588555

Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015588555

Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015588555

Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015588555

Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015588555

Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015588555

Immediate and long-term somatic effects, and health-related quality of life of BM donation during early childhood. A single-center report in 210 pediatric donors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015588555

The effect of dexamethasone on polyclonal T cell activation and redirected target cell lysis as induced by a CD19/CD3-bispecific single-chain antibody construct

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015588555

Toxicity management for patients receiving novel T-cell engaging therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015588555

Current concepts in the diagnosis and management of cytokine release syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015588555

Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015588555

Chimeric antigen receptor-modified T cells for acute lymphoid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015588555

Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015588555

Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015588555

Outcome of adults with acute lymphocytic leukemia after second salvage therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015588555

Sorafenib in patients with refractory or recurrent multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015588555

21 January 2018

Identifiers

DOI

10.1177/1060028015588555

1 reference

3 September 2017

1 reference